Synaptogenix Inc (SNPX)

[InTheTrenches]

3rd party confirmation that 2-73 achieves it.

pre-clinical data...2-73 needs double-blind placebo-controlled trials. Neurotrope well down that path already.

Neurotrope is no further along in the trial process than Anavex is

Neurotrope much further along--see above, double-blind, placebo-controlled trials.

but Anavex has patients with many years of CONTINUOUS use and safety data.

But AVXL has no double-blind, placebo-controlled results...won't have them for a few years.

Bryostatin MOA is not unique and 2-73 appears to do it better, and at a lower cost because the drug is small molecule can be manufactured economically.

Bryostatin MOA IS unique.

Cost doesn't matter unless you have run a well-controlled trial. Can't get approval without a double-blind trial.

"Appears" doesn't cut it with regulatory agencies. AVXL needs to prove it with a trial.

Oh, by the way, Bryostatin IS a small molecule drug.

It's a good thing because it seems to address a systemic remedy to the effects of old age.

"Seems" doesn't cut it with regulatory agencies. AVXL needs to prove it with a real trial.